Dual binding site inhibitors of B-RAF kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 9, 2008, Pages 2825-2829

  Wolin, Ronald L ^a   Bembenek, Scott D ^a   Wei, Jianmei ^a   Crawford, Shelby ^a   Lundeen, Katherine ^a   Brunmark, Anders ^a   Karlsson, Lars ^a   Edwards, James P ^a   Blevitt, Jonathan M ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

B RAF; Diarylimidazoles; Kinase inhibitors

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANALYTIC METHOD; ARTICLE; BINDING SITE; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC SITE; COMPUTER-AIDED DESIGN; CRYSTALLOGRAPHY, X-RAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HYDROCARBONS, AROMATIC; IMIDAZOLES; INHIBITORY CONCENTRATION 50; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42949146089     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.002     Document Type: Article

References (16)

1. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Nature 417 (2002) 949
2. Bollag G., Freeman S., Lyons J.F., and Post L.E. Curr. Opin. Invest. Drugs 4 (2003) 1436
3. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Cell 116 (2004) 855
4. Pratilas C.A., and Solit D.B. Rev. Recent Clin. trials 2 (2007) 121 and references therein
5. For example, human liver microsome stability values for the parent compounds 1 and 2 were 48% and 87% remaining after 15 min, respectively. The values for 1 and 2 in rat liver microsomes were 40% and 11%, respectively. Solubility values for 1 was 87 μM and for 2 was >100 μM at pH 7.4 (phosphate buffer).
6. Khire U.R., Bankston D., Barbosa J., Brittelli D.R., Caringal Y., Carlson R., Dumas J., Gane T., Heald S.L., Hibner B., Johnson J.S., Katz M.E., Kennure N., Kingery-Wood J., Lee W., Liu X.G., Lowinger T.B., McAlexander I., Monahan M.K., Natero R., Renick J., Riedl B., Rong H., Sibley R.N., Smith R.A., and Wolanin D. Bioorg. Med. Chem. Lett. 14 (2004) 783
7. Nahm S., and Weinreb S.M. Tetrahedron Lett. 22 (1981) 3815
8. Maryanoff, B. E.; Kinny, W. A.; Lawson, E. C.; Luci, D. K.; Marchenko, N.; Sviridov, S. International Patent Application Number; WO2007/081995, pg 243 describes preparation of the N-Boc carbamate (29b) in place of the ethyl carbamate analog used to prepare 7 in Scheme 1.
9. Kornblum N., Powers J.W., Anderson G.J., Jones W.J., Larson H.O., Levand O., and Weaver W.M. J. Am. Chem. Soc. 79 (1957) 6562
10. 50 values >100 nM in the B-RAF kinase assay did not meet the criteria for progression though the remaining portions of our assay paradigm.
11. 18, Agilent HPLC). Standards of 100, 10, and 1 μM were prepared in DMSO to generate a standard curve. Compound concentrations were determined by extrapolating peak areas from the standard curve generated from a linear regression analysis in Graph Pad Prism (GraphPad Software, San Diego, CA). The calculated Log P values for compounds 17-19 are 3.13, 4.20, and 5.07, respectively.
12. 50 values for the sulfonamide analogs 14-16, the (NHMe) substituent still ranks favorably for displaying excellent B-RAF kinase inhibition (Table 1).
13. a values of ∼5.8 versus ∼11.8 for the cyclopropyl analogs 17-19.
14. Crawford S., Belajic D., Wei J., Riley J.P., Dunford P.J., Bembenek S., Fourie A., Edwards J.P., Karlsson L., Brunmark A., Wolin R.L., and Blevitt J.M. Mol. Can. Ther. 7 (2008) 492
15. Upstate (Millipore) kinase panel. Millipore Corp. 290 Concord Rd. Billerica, MA 01821.
16. Takle A.K., Brown M.J.B., Davies S., Dean D.K., Francis G., Gaiba A., Hird A.W., King F.D., Lovell P.J., Naylor A., Reith A.D., Steadman J.G., and Wilson D.M. Bioorg. Med. Chem. Lett. 16 (2006) 378